No abstract available
MeSH terms
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / analysis
-
Combined Modality Therapy
-
Drug Approval
-
Humans
-
Immunotherapy / methods
-
Melanoma / drug therapy
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Nivolumab
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Skin Neoplasms / drug therapy
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
pembrolizumab